Drugs.com - New Drug Approvals

FDA Grants Isturisa (osilodrostat) Expanded Indication for the Treatment of Endogenous Hypercortisolemia in Patients with Cushing’s Syndrome

Milan, Italy and Bridgewater, NJ, April 16, 2025 – Today Recordati announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the treatment of endogenous...

May 12, 2025 - 10:14
 0
Milan, Italy and Bridgewater, NJ, April 16, 2025 – Today Recordati announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the treatment of endogenous...
Read More

Tags:

Previous Article

FDA Approves Mezofy (aripiprazole) Oral Film for the Treatment of Schizophrenia

Next Article

Neurelis Announces FDA Approval for Immediate Use Seizure Medication Valtoco (di...

Related Posts

FDA Approves Gozellix (kit for the preparation of galli...

May 12, 2025  0

Uplizna (inebilizumab-cdon) is Now the First and Only F...

May 12, 2025  0

U.S. FDA Approves Third Indication of Nubeqa (darolutamide) for Patients with Advanced Prostate cancer

U.S. FDA Approves Third Indication of Nubeqa (darolutam...

Jun 5, 2025  0